HOUSTON, November 19, 2025 — Leads & Copy — FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology firm, has announced a definitive agreement for a registered direct offering priced at-the-market, expected to generate approximately $4 million before deducting expenses.
The offering involves the issuance and sale of 3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares to an existing shareholder at $0.3303 per share or pre-funded warrant (less $0.00001 for each pre-funded warrant). The pre-funded warrants are exercisable at any time at an exercise price of $0.00001 per share and do not expire.
In a concurrent private placement, FibroBiologics will issue unregistered warrants to purchase one share of common stock for each share purchased in the direct offering, totaling up to 12,110,203 shares. These unregistered warrants have an exercise price of $0.3303 per share and become exercisable upon stockholder approval, expiring five years after the approval date.
The purchase price for the shares will be paid with sovereign-issued .9999 fine gold coins, valued at $4,069.18 per ounce based on the spot price at the time of signing the purchase agreement. The company intends to liquidate the gold into United States dollars.
FibroBiologics intends to use the net proceeds from the offering for general corporate purposes, including debt satisfaction.
The offering is expected to close around November 19, 2025, pending customary closing conditions.
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, expressed gratitude for the continued support from a major shareholder, stating that it provides flexibility to strengthen the company’s capital structure and focus on building the future.
The shares of common stock and pre-funded warrants in the registered direct offering are offered via a shelf registration statement on Form S-3, previously declared effective by the SEC.
The unregistered warrants and associated shares were offered privately under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D and are subject to resale restrictions.
This announcement is not an offer to sell or a solicitation of an offer to buy securities.
Nic Johnson, Investor Relations, Russo Partners, (212) 845-4242, fibrobiologicsIR@russopr.com
Liz Phillips, Media Contact, Russo Partners, (347) 956-7697, Elizabeth.phillips@russopartnersllc.com
Source: FibroBiologics
